Prostemics Co. Ltd
Ark Solutions Inc. engages in the research and development of products using protein in South Korea, Japan, Mexico, and internationally. It operates through Life and Health Business and Exosome Business divisions. The company offers products using stem cells. The company also provides cosmetics for hospitals and clinics, such as AAPE, a products containing high concentration human cell culture me… Read more
Prostemics Co. Ltd (203690) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.137x
Based on the latest financial reports, Prostemics Co. Ltd (203690) has a cash flow conversion efficiency ratio of -0.137x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.17 Billion) by net assets (₩30.37 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prostemics Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how Prostemics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Prostemics Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prostemics Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
0.098x |
|
Ray Co. Ltd
KQ:228670
|
0.053x |
|
Jaanh CosmeticsInc.
KQ:219550
|
-0.295x |
|
Tristar Gold
OTCQB:TSGZF
|
-0.024x |
|
CHA Vaccine Institute Co. Ltd.
KQ:261780
|
-0.140x |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
-0.020x |
|
ONDE S.A. ZY -02
F:0XF
|
N/A |
|
Singapore Shipping Corporation Limited
F:W1M
|
0.034x |
Annual Cash Flow Conversion Efficiency for Prostemics Co. Ltd (2015–2023)
The table below shows the annual cash flow conversion efficiency of Prostemics Co. Ltd from 2015 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | ₩30.43 Billion | ₩-6.84 Billion | -0.225x | +53.77% |
| 2022-12-31 | ₩9.83 Billion | ₩-4.78 Billion | -0.486x | -325.35% |
| 2021-12-31 | ₩13.93 Billion | ₩3.00 Billion | 0.216x | +199.11% |
| 2020-12-31 | ₩21.47 Billion | ₩-4.67 Billion | -0.218x | -1349.04% |
| 2019-12-31 | ₩28.35 Billion | ₩-425.74 Million | -0.015x | +79.48% |
| 2018-12-31 | ₩31.89 Billion | ₩-2.33 Billion | -0.073x | +13.86% |
| 2017-12-31 | ₩39.16 Billion | ₩-3.33 Billion | -0.085x | -164.99% |
| 2016-12-31 | ₩44.86 Billion | ₩5.86 Billion | 0.131x | -17.60% |
| 2015-12-31 | ₩39.38 Billion | ₩6.25 Billion | 0.159x | -- |